AlphAIAlphAI — Financial news for AI agents
investing.comOCT 132 min read$SNDX

Stifel maintains Syndax stock rating after trial failure

Stifel maintained its Buy rating and $40 price target on Syndax Pharmaceuticals (SNDX) after the company's Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed. Syndax will halt further development of the drug for this indication. Stifel noted the setback but kept its positive outlook on Revuforj revenue growth and Niktimvo's potential. SNDX shares fell about 15% post-announcement, trading near their 52-week low.

Original reporting
investing.com
Published Oct 13, 2026, 2:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SNDX
Bearish
high confidence
Mentioned
$SNDX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SNDXBearishMed
01

Why it matters

The negative trial result is likely to trigger a sell‑off, especially given the recent ~15% post‑close price drop.

02

Market read

First‑report of a Phase 2 failure for a mid‑cap biotech; material for traders monitoring biotech sector momentum.

03

What to watch

Analysts still see value in other product candidates and potential label expansions, which could cushion the downside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Syndax Pharmaceuticals (NASDAQ:SNDX) focuses on treatments for idiopathic pulmonary fibrosis and graft‑versus‑host disease. The failed Phase 2 trial removes a key asset from its IPF pipeline.

Company-level read

Ticker impact

$SNDXBearishHigh confidence
Context

Syndax announced its Phase 2 MAXPIRe trial failed to meet the primary endpoint, prompting analysts to maintain ratings but note a ~15% post‑close share decline.

Expected impact

downward pressure as investors price in the loss of a pipeline asset

Evidence & confidence

Clinical‑trial data is a primary, material disclosure for a biotech; the negative result is likely to drive the stock lower in the short term.

Market effects

Sector

May weigh on other IPF‑focused biotech stocks as the trial highlights challenges in the monocyte/macrophage axis.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond investors tracking biotech pipelines.

Counterpoint

What could challenge this read

If the market overreacts, the stock could rebound on the strength of Revuforj and Niktimvo pipelines.

Key entities

  • company
    Syndax Pharmaceuticals

    Biotech firm developing axatilimab and other therapies.

  • analyst
    Stifel

    Maintained Buy rating and $40 price target despite trial failure.

Read at source← All news

StorySyndax halts axatilimab development for idiopathic pulmonary fibrosis after Phase 2 miss

Also covered by

1 outlet

Related articles

NOV 2
$SNDXHighAI 8/10

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R

SEC EDGAR 8-K2 min
NOV 2
$SNDXLow

Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end

Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.

stocktitan.net1 min
NOV 2
$SNDXMed

About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.

Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.

stocktitan.net2 min
OCT 14
$SNDXMedAI 8/10

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.

zacks.com2 min
OCT 13
$CMed

Crude Oil Edges Higher; Citigroup Earnings Top Views

Citigroup (NYSE:C) reported Q3 earnings of $2.85 per share, beating estimates. Bumble (NASDAQ:BMBL) surged 56% after a buyout deal. BIO-Key (NASDAQ:BKYI) rose 139% on a government security contract. Fermi (NASDAQ:FRMI) gained 21% on a credit agreement. Pershing Square (NYSE:PS) fell 11% after a downgrade. Cipher Digital (NASDAQ:CIFR) dropped 14% on a convertible notes offering. Syndax (NASDAQ:SNDX) declined 17% after a trial failure. Oil rose 0.4% to $94.13, while gold and silver fell.

benzinga.com7 min